Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

A groundbreaking study has shed light on a remarkable development in the global non-infectious macular edema treatment market. The surge in diabetes-related complications and increased awareness of eye-related ailments across various regions have fueled a growing demand for effective treatments for macular edema. This surge in demand has led to a proliferation of treatment options in the market, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and more. Anti-VEGF treatments have traditionally dominated the market, and they are expected to maintain the highest market share during the forecast period.

Transition Away from Anti-VEGF Toward Corticosteroids

However, the Anti-VEGF market is anticipated to witness a gradual decline in usage due to heightened awareness of potential side effects associated with the drug. Systemic immunomodulatory treatment is poised to reduce reliance on Anti-VEGF medications. Notably, Corticosteroids are projected to experience an exceptional surge in demand in the coming years, with the market expected to grow at a stellar rate during the forecast period.

Intravitreal Implants and Immunosuppressants Triggering Market Growth

The recent approval of Intravitreal Implants for macular edema treatment has catalyzed market growth. The introduction of three new products - Eylea, Ozurdex, and Iluvien - has led to increased adoption of intravitreal medications, particularly in North America. Intravitreally injected medications were less commonly used in North America and European countries, where laser photocoagulation was the primary treatment method before the launch of Lucentis in 2012.

The rising adoption of Intravitreal therapies can be attributed to the availability of low-dose, high-efficacy corticosteroid implants for Intravitreal use. Patients are increasingly turning to Intravitreal implants, driving global demand for macular edema treatment.

Immunosuppressant Therapies Enhance Treatment Efficacy

Immunosuppressant therapies, often used in conjunction with corticosteroids, play a vital role in the treatment of macular edema. These therapies are typically added to corticosteroid regimens to reduce the need for high doses of systemic steroids or used independently as steroid-sparing agents when steroid treatment is not well-tolerated.

For example, three immunomodulators - methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate mofetil (MMF, Cellcept) - have proven to be highly effective in achieving disease quiescence and are well-tolerated by patients. These immunosuppressants have emerged as efficient treatment options, driving demand in the global market for non-infectious macular edema treatment.

Challenges in the Global Macular Edema Market

While the market exhibits significant growth potential, challenges persist. Many patients and ophthalmologists opt for alternative treatments over Anti-VEGF and corticosteroids due to the repeated injections and high costs associated with these drugs. Non-compliance with treatment schedules, resulting in missed injections, can lead to irreversible damage and permanent vision loss in diabetic macular edema (DME) patients.

Additionally, counterfeit and off-label drugs are readily available in the global market. The launch of biosimilars for some blockbuster anti-VEGF agents is expected to further impact the market by reducing opportunities for branded and patented drugs.

Market Segmentation

Drug Type

Anti-VEGF
Corticosteroids
Immunosuppressant
Biologics
Others

Indication

Non-infectious Uveitic Macular Edema
Diabetic Macular Edema
Retinal Vein Occlusion with Macular Edema

Route of Administration

Oral
Parenteral
Topical

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Region

North America
Latin America
Europe
Japan
MEA
APAC

1. Executive Summary

1.1. Global Non-infectious Macular Edema Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

3.1. Global Non-infectious Macular Edema Treatment Market Production Output, by Region, Value (US$ Mn), 2018 - 2023
- 3.1.1. North America
- 3.1.2. Europe
- 3.1.3. Asia Pacific
- 3.1.4. Latin America
- 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

4.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2018 - 2023
4.2. Prominent Factor Affecting Non-infectious Macular Edema Treatment Prices
4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

5.1. Global Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Anti-VEGF
  - 5.1.1.2. Corticosteroids
  - 5.1.1.3. Immunosuppressant
  - 5.1.1.4. Biologics
  - 5.1.1.5. Others
5.2. Global Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Non-infectious Uveitic Macular Edema
  - 5.2.1.2. Diabetic Macular Edema
  - 5.2.1.3. Retinal Vein Occlusion with Macular Edema
5.3. Global Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Parenteral
  - 5.3.1.3. Topical
5.4. Global Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Hospital Pharmacies
  - 5.4.1.2. Retail Pharmacies
  - 5.4.1.3. Online Pharmacies
5.5. Global Non-infectious Macular Edema Treatment Market Outlook, by Region, Value (US$ Mn) and Volume, 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. North America
  - 5.5.1.2. Europe
  - 5.5.1.3. Asia Pacific
  - 5.5.1.4. Latin America
  - 5.5.1.5. Middle East & Africa

6. North America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

6.1. North America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Anti-VEGF
  - 6.1.1.2. Corticosteroids
  - 6.1.1.3. Immunosuppressant
  - 6.1.1.4. Biologics
  - 6.1.1.5. Others
6.2. North America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Non-infectious Uveitic Macular Edema
  - 6.2.1.2. Diabetic Macular Edema
  - 6.2.1.3. Retinal Vein Occlusion with Macular Edema
6.3. North America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Parenteral
  - 6.3.1.3. Topical
6.4. North America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Hospital Pharmacies
  - 6.4.1.2. Retail Pharmacies
  - 6.4.1.3. Online Pharmacies
6.5. North America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. U.S. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.2. U.S. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.3. U.S. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.4. U.S. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.5. Canada Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.6. Canada Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.7. Canada Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 6.5.1.8. Canada Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

7.1. Europe Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Anti-VEGF
  - 7.1.1.2. Corticosteroids
  - 7.1.1.3. Immunosuppressant
  - 7.1.1.4. Biologics
  - 7.1.1.5. Others
7.2. Europe Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Non-infectious Uveitic Macular Edema
  - 7.2.1.2. Diabetic Macular Edema
  - 7.2.1.3. Retinal Vein Occlusion with Macular Edema
7.3. Europe Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Parenteral
  - 7.3.1.3. Topical
7.4. Europe Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Hospital Pharmacies
  - 7.4.1.2. Retail Pharmacies
  - 7.4.1.3. Online Pharmacies
7.5. Europe Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Germany Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.2. Germany Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.3. Germany Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.4. Germany Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.5. U.K. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.6. U.K. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.7. U.K. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.8. U.K. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.9. France Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.10. France Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.11. France Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.12. France Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.13. Italy Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.14. Italy Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.15. Italy Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.16. Italy Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.17. Turkey Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.18. Turkey Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.19. Turkey Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.20. Turkey Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.21. Russia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.22. Russia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.23. Russia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.24. Russia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.25. Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.26. Rest of Europe Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.27. Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 7.5.1.28. Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

8.1. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Anti-VEGF
  - 8.1.1.2. Corticosteroids
  - 8.1.1.3. Immunosuppressant
  - 8.1.1.4. Biologics
  - 8.1.1.5. Others
8.2. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Non-infectious Uveitic Macular Edema
  - 8.2.1.2. Diabetic Macular Edema
  - 8.2.1.3. Retinal Vein Occlusion with Macular Edema
8.3. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Parenteral
  - 8.3.1.3. Topical
8.4. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Hospital Pharmacies
  - 8.4.1.2. Retail Pharmacies
  - 8.4.1.3. Online Pharmacies
8.5. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. China Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.2. China Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.3. China Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.4. China Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.5. Japan Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.6. Japan Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.7. Japan Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.8. Japan Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.9. South Korea Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.10. South Korea Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.11. South Korea Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.12. South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.13. India Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.14. India Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.15. India Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.16. India Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.17. Southeast Asia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.18. Southeast Asia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.19. Southeast Asia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.20. Southeast Asia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.21. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.22. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.23. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 8.5.1.24. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

9.1. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
- 9.1.1. Key Highlights
  - 9.1.1.1. Anti-VEGF
  - 9.1.1.2. Corticosteroids
  - 9.1.1.3. Immunosuppressant
  - 9.1.1.4. Biologics
  - 9.1.1.5. Others
9.2. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
- 9.2.1. Key Highlights
  - 9.2.1.1. Non-infectious Uveitic Macular Edema
  - 9.2.1.2. Diabetic Macular Edema
  - 9.2.1.3. Retinal Vein Occlusion with Macular Edema
9.3. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
- 9.3.1. Key Highlights
  - 9.3.1.1. Oral
  - 9.3.1.2. Parenteral
  - 9.3.1.3. Topical
9.4. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 9.4.1. Key Highlights
  - 9.4.1.1. Hospital Pharmacies
  - 9.4.1.2. Retail Pharmacies
  - 9.4.1.3. Online Pharmacies
9.5. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
- 9.5.1. Key Highlights
  - 9.5.1.1. Brazil Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.2. Brazil Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.3. Brazil Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.4. Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.5. Mexico Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.6. Mexico Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.7. Mexico Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.8. Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.9. Argentina Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.10. Argentina Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.11. Argentina Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.12. Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.13. Rest of Latin America Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.14. Rest of Latin America Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.15. Rest of Latin America Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 9.5.1.16. Rest of Latin America Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

10.1. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
- 10.1.1. Key Highlights
  - 10.1.1.1. Anti-VEGF
  - 10.1.1.2. Corticosteroids
  - 10.1.1.3. Immunosuppressant
  - 10.1.1.4. Biologics
  - 10.1.1.5. Others
10.2. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
- 10.2.1. Key Highlights
  - 10.2.1.1. Non-infectious Uveitic Macular Edema
  - 10.2.1.2. Diabetic Macular Edema
  - 10.2.1.3. Retinal Vein Occlusion with Macular Edema
10.3. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
- 10.3.1. Key Highlights
  - 10.3.1.1. Oral
  - 10.3.1.2. Parenteral
  - 10.3.1.3. Topical
10.4. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 10.4.1. Key Highlights
  - 10.4.1.1. Hospital Pharmacies
  - 10.4.1.2. Retail Pharmacies
  - 10.4.1.3. Online Pharmacies
10.5. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
- 10.5.1. Key Highlights
  - 10.5.1.1. GCC Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.2. GCC Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.3. GCC Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.4. GCC Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.5. South Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.6. South Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.7. South Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.8. South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.9. Egypt Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.10. Egypt Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.11. Egypt Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.12. Egypt Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.13. Nigeria Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.14. Nigeria Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.15. Nigeria Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.16. Nigeria Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.17. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.18. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.19. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
  - 10.5.1.20. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
- 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

11.1. Product vs Indication Heatmap
11.2. Company Market Share Analysis, 2023
11.3. Competitive Dashboard
11.4. Company Profiles
- 11.4.1. Pfizer, Inc.
  - 11.4.1.1. Company Overview
  - 11.4.1.2. Product Portfolio
  - 11.4.1.3. Financial Overview
  - 11.4.1.4. Business Strategies and Development
- 11.4.2. Novartis AG
  - 11.4.2.1. Company Overview
  - 11.4.2.2. Product Portfolio
  - 11.4.2.3. Financial Overview
  - 11.4.2.4. Business Strategies and Development
- 11.4.3. F. Hoffman - La Roche Ltd.
  - 11.4.3.1. Company Overview
  - 11.4.3.2. Product Portfolio
  - 11.4.3.3. Financial Overview
  - 11.4.3.4. Business Strategies and Development
- 11.4.4. AbbVie Inc
  - 11.4.4.1. Company Overview
  - 11.4.4.2. Product Portfolio
  - 11.4.4.3. Financial Overview
  - 11.4.4.4. Business Strategies and Development
- 11.4.5. Bayer AG
  - 11.4.5.1. Company Overview
  - 11.4.5.2. Product Portfolio
  - 11.4.5.3. Financial Overview
  - 11.4.5.4. Business Strategies and Development
- 11.4.6. Valeant Pharmaceuticals Inc
  - 11.4.6.1. Company Overview
  - 11.4.6.2. Product Portfolio
  - 11.4.6.3. Financial Overview
  - 11.4.6.4. Business Strategies and Development
- 11.4.7. Alimera Sciences Inc
  - 11.4.7.1. Company Overview
  - 11.4.7.2. Product Portfolio
  - 11.4.7.3. Financial Overview
  - 11.4.7.4. Business Strategies and Development
- 11.4.8. Clearside Biomedical, Inc
  - 11.4.8.1. Company Overview
  - 11.4.8.2. Product Portfolio
  - 11.4.8.3. Financial Overview
  - 11.4.8.4. Business Strategies and Development

12. Appendix

12.1. Research Methodology
12.2. Report Assumptions
12.3. Acronyms and Abbreviations